INDIANAPOLIS, Oct. 7, 2010 (GLOBE NEWSWIRE) -- Positron Corporation (OTCBB:POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, commented on the new medical radiation bill passed into law in California.
Last week, Governor Arnold Schwarzenegger of California signed a medical radiation protection bill (SB1237) into law, paving the way for implementation of the first state law in the U.S. aimed at protecting patients from excessive radiation exposure received during CT scans and radiation therapy procedures. The law's passage comes on the heels of an overwhelming increase of reported incidents of patients being exposed to excess radiation both in California and throughout the country.
"We believe the passage of this bill will create awareness, and generate further discussion on the proper guidelines and procedures on minimizing radiation exposure to patients. Positron is well-positioned to be in accordance with the new California regulations by offering customers a CT-free solution with our Attrius dedicated PET scanner. The Attrius was specifically engineered to address the underlying consensus of the radiology community – to follow the ALARA principal (as low as reasonably achievable), in reducing radiation exposure to the lowest level possible.
"This is not an issue specific to California; we are pleased to offer a safe viable alternative to the greater medical community," stated Joseph Oliverio, CTO of Positron.
SB 1237, which the governor signed without comment, will impose strict new procedures and reporting requirements to protect patients from medical radiation overdoses when it becomes effective July 1, 2012.
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. More information about Positron is available at .
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
CONTACT: Positron Corporation (317) 576-0183
